circRNA basic information
circBase ID: hsa_circ_0007991
Name: hsa_circ_EIF4G3
Synonym: circEIF4G3
Host Gene: EIF4G3
Genomic location(hg19): chr1:21329205-21415706:-
Genomic location(hg38): chr1:21002712-21089213:-
Subcellular localization: cytoplasm
 
 
 
 
 
 
 
Disease basic information
MONDO ID:
 0001056
MONDO name: gastric cancer
Disease details: gastric cancer / GC
Disease DO ID:
 10534
Disease MeSH ID:
 -
Disease NCIt ID:
 C9331
Disease ICD11 ID:
 1397617262
Disease OMIM ID:
 613659
Species: Human
Species details: Homo sapiens
Tissue specimen:

tumor tissues; adjacent non-tumor tissues; serum
Cell lines:

AGS; HGC-27; MKN-45; SGC-7901; HEK-293T; GES-1; NCI-N87
In vivo animal model:

cell line-derived xenograft
circRNA-disease information
Expression pattern:
DN
Associated gene: delta-catenin, TRIM25, SIK1, beta-catenin, c-Myc, cyclin D1, Ago2
Associated microRNA: miR-4449
Biological function: Suppresses gastric cancer growth and metastasis; inhibits proliferation, migration and invasion; promotes apoptosis; inhibits EMT-like marker changes
Molecular mechanism: Binds delta-catenin and acts as a scaffold to enhance TRIM25-mediated ubiquitination and proteasomal degradation of delta-catenin, leading to inhibition of beta-catenin signaling; acts as a miRNA sponge for miR-4449 to upregulate SIK1 and inactivate beta-catenin signaling
Biological pathway or process:

Wnt/beta-catenin (inhibits); proliferation (inhibits); migration (inhibits); invasion (inhibits); metastasis (inhibits); apoptosis (promotes); cell cycle (inhibits); EMT (inhibits); ceRNA regulation (promotes); ubiquitination (promotes)
Detected method:
Q
M
Validation methods:

Microarray; Bioinformatics Analysis; RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RNase R Treatment; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; Survival Analysis; ROC Analysis; Transfection; CCK8; Colony Formation Assay; Transwell Assay; Annexin V/PI Flow Cytometry; Cell Cycle Assay; RNA Pull-Down; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; RNA-seq; Western Blot; Co-IP; In Vivo Animal Model; H&E Staining; IHC (Immunohistochemistry)
Clinical significance:

Lower circEIF4G3 level predicts poor prognosis; serum circEIF4G3 shows diagnostic value for GC (AUC 0.797)
Description:

circEIF4G3 (hsa_circ_0007991), derived from EIF4G3, is downregulated in gastric cancer tissues and serum and is associated with poor outcomes. Functionally, it suppresses GC proliferation and metastasis and promotes apoptosis. Mechanistically, it inhibits Wnt/beta-catenin signaling by promoting TRIM25-mediated ubiquitination/degradation of delta-catenin and by sponging miR-4449 to upregulate SIK1.
Confidence score:

0.8989
Other information
Title:

Circular RNA EIF4G3 suppresses gastric cancer progression through inhibition of beta-catenin by promoting delta-catenin ubiquitin degradation and upregulating SIK1.

Journal: Molecular cancer
Published: 2022
PubMed ID: 35780119
Study type:

combined biological and clinical study
Data availability: GSE89143; GSE78092; GSE93541; TCGA
Code availability: -